MOLECULAR INSIGHT (NASDAQ:MIPI)
4.23
+0.04 (0.95%)
| MOLECULAR INSIGHT (NASDAQ:MIPI) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $4.19 | 52 Week High | $7.90 | ||
| Open | $4.16 | 52 Week Low | $1.15 | ||
| Day High | $4.58 | P/E | N/A | ||
| Day Low | $4.12 | EPS | $-2.89 | ||
| Volume | 27,715 | ||||
| More MIPI Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| STSI | 2 | SVNT | 2 |
| ALVR | 2 | ETFC | 2 |
| RAI | 2 | NNI | 2 |
| CLNE | 1 | WEL | 1 |
| NPBC | 1 | HOO | 1 |
| MERX | 1 | ALCO | 1 |
Entities who have mentioned MIPI
- Dividend | View Related Stories »
- Life, Style and Real Estate | View Related Stories »
- Stock Buyback | View Related Stories »
- Cowen & Co | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Bankruptcy | View Related Stories »
- Keefe, Bruyette & Woods | View Related Stories »
- Robert W Baird | View Related Stories »
- Standard & Poor's | View Related Stories »
- Trading Radar | View Related Stories »
- Brean Murray Carret & Co. | View Related Stories »
- Lazard | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Wedbush Morgan | View Related Stories »
- Barack Obama | View Related Stories »
View All ReportsStreetInsider.com Reports on MIPI
- Molecular Insight Pharma (MIPI) Executes 10-Year Agreement to Supply Onalta to BioMedica Life Sciences
- Brean Murray Initiates Coverage on Molecular Insight Pharmaceuticals (MIPI) with a Buy
- Molecular Insight (MIPI) Said Azedra Study Demonstrates Positive Safety Profile and Durable Objective Tumor Responses
- Trading Radar for 8/10: DISH (DISH), Echostar (SATS), SYSCO (SYY), Fluor (FLR), Rackspace (RAX), priceline.com (PCLN) Report
- Unusual 11 Mid-Day Movers 6/18: NPBC, NNI, STSI, MIPI Higher; MTMC, BZH, YRCW, TSFG Lower
View All Press ReleasesCompany Press Releases on MIPI
- Molecular Insight Pharmaceuticals to Present at Lazard Capital Markets Annual Healthcare Conference
- Molecular Insight Pharmaceuticals Reports Third Quarter 2009 Financial Results
- Molecular Insight Pharmaceuticals, Inc. to Report Third Quarter Financial Results on November 9, 2009
- Molecular Insight Pharmaceuticals Finalizes Onalta(TM) Manufacturing and Supply Agreements
- Molecular Insight Pharmaceuticals Presents Azedra(TM) 12-Month Efficacy Data From Phase I Clinical Trial in Neuroendocrine Tumors
StreetInsider Reports on MIPI by Category
View All BlogsBlogs on MIPI
- Biotech Busy with Bevy of Small Deals
- Three Top and Bottom Market Sectors for This Week
- Molecular Insight Pharmaceuticals: Two Promising Candidates to Battle Prostate Cancer
- 20 Stocks Which May Be Threatening Your Portfolio
- 20 Stocks to Avoid from Russell 2000
View All FilingsSEC Filings on MIPI
- Form 4 Molecular Insight Pharma For: Nov 17 Filed by: Abdalian Charles H Jr
- Form 8-K Molecular Insight Pharma For: Nov 09
- Form 10-Q Molecular Insight Pharma For: Sep 30
- Form 8-K Molecular Insight Pharma For: Oct 20
Comments on MIPI
No comments are currently available.
